FCGRT Fc gamma receptor and transporter
ENSG00000104870 · protein coding · Open Targets profile
Cell surface receptor that transfers passive humoral immunity from the mother to the newborn. Binds to the Fc region of monomeric immunoglobulin gamma and mediates its selective uptake from milk (PubMed:10933786, PubMed:7964511). IgG in the milk is bound at the apical surface of the intestinal epithelium. The resultant FcRn-IgG complexes are transcytosed across the intestinal epithelium and IgG is released from FcRn into blood or tissue fluids. Throughout life, contributes to effective humoral immunity by recycling IgG and extending its half-life in the circulation. Mechanistically, monomeric IgG binding to FcRn in acidic endosomes of endothelial and hematopoietic cells recycles IgG to the cell surface where it is released into the circulation (PubMed:10998088). In addition of IgG, regulates homeostasis of the other most abundant circulating protein albumin/ALB (PubMed:24469444, PubMed:28330995). {ECO:0000250|UniProtKB:P13599, ECO:0000269|PubMed:10933786, ECO:0000269|PubMed:10998088, ECO:0000269|PubMed:24469444, ECO:0000269|PubMed:28330995, ECO:0000269|PubMed:7964511}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand
- Antibody
- Approved Drug, UniProt loc high conf, UniProt loc med conf, UniProt SigP or TMHMM, GO CC med conf
- PROTAC
- Half-life Data, Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.36434000730514526 (upper bound 0.5792499780654907). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 69 registry trials, updated in the last three years, of the most advanced drugs against FCGRT (nipocalimab, efgartigimod alfa, rozanolixizumab, batoclimab, orilanolimab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- UCB Cares001 844 599 2273 · 13 of 15 trials Phase 2+Ph3NCT06540144 · An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravisbrief
- Antonio Gugliettaargenx · 1 of 1 trials Phase 2+
- Colin QuinnStaff Physician and Associate Professor of Clinical Neurology · 1 of 1 trials Phase 2+
- François JacquesClinique Neuro-Outaouais · 1 of 1 trials Phase 2+
- Marshall MazepaUniversity of Minnesota · 1 of 1 trials Phase 2+
- Matt P MarinkovichAssociate Professor of Dermatology · 1 of 1 trials Phase 2+
- Matthew C BakerStanford University · 1 of 1 trials Phase 2+
- Thomas RagoleUniversity of Colorado, Denver · 1 of 1 trials Phase 2+
- Tuan H VuUniversity of South Florida · 1 of 1 trials Phase 2+
- Vera BrilToronto General Hospital · 1 of 1 trials Phase 2+
Registry trials of nipocalimab, efgartigimod alfa, rozanolixizumab, batoclimab, orilanolimab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 23 of 63 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 6 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
16 trials of drugs against FCGRT were stopped early
Terminated, withdrawn and suspended interventional trials of nipocalimab, efgartigimod alfa, rozanolixizumab, batoclimab, orilanolimab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 16 most recent of 16.
- terminated · 2026-09-14 · Immunovant Sciences GmbH · Batoclimab 680 mg SC weekly, Batoclimab 340 mg SC weekly, Batoclimab 340 mg SC bi-weekly“Sponsor Decision”
- terminated · 2026-08-11 · Immunovant Sciences GmbH · Batoclimab“Sponsor Decision”
- terminated · 2026-08-11 · Immunovant Sciences GmbH · Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Batoclimab 340 mg SC weekly“Sponsor Decision”
- terminated · 2026-04-29 · Immunovant Sciences GmbH · Batoclimab“The feeder studies (i.e., IMVT-1401-3201 and 3202) for study IMVT-1401-3203 failed to achieve their pre-defined primary efficacy outcomes. Accordingly, there was a change to the benefit-risk balance. No new safety findings were observed.”
- withdrawn · 2026-03-12 · Chafic Karam · Efgartigimod Alfa-Fcab“Study will not be proceeding due to continued difficulties with participant enrollment at a single site.”
- withdrawn · 2026-02-27 · Janssen Research & Development, LLC · Nipocalimab“Business Decision”
- terminated · 2025-10-23 · argenx · matched by the registry's drug synonyms“Due to the phase 2 results of the main study (ARGX-113-2104) showing that efgartigimod-treated PC-POTS patients had no clinically meaningful improvement, the decision has been made to terminate this open-label extension study (ARGX-113-2105) study.”
- terminated · 2025-05-31 · UCB Biopharma SRL · Rozanolixizumab“The study stopped prematurely due to enrolment challenges, the termination was not linked to any safety issues.”
- terminated · 2025-03-18 · UCB Biopharma SRL · Rozanolixizumab“Strategic Business Decision; Not a safety decision”
- terminated · 2024-02-05 · UCB Biopharma SRL · Rozanolixizumab“Strategic Business Decision; Not a safety decision”
- terminated · 2023-08-08 · UCB Biopharma SRL · Rozanolixizumab“Strategic Business Decision; Not a safety decision”
- withdrawn · 2022-02-11 · Alexion Pharmaceuticals, Inc. · matched by the registry's drug synonyms“Sponsor decision to terminate program”
- withdrawn · 2020-09-14 · argenx · matched by the registry's drug synonyms“The ARGX-113-1908 study will be replaced by a similar design with a subcutaneous formulation (ARGX-113-2004)”
- withdrawn · 2020-07-13 · Alexion Pharmaceuticals, Inc. · matched by the registry's drug synonyms“Study is withdrawn due to the global impact of the COVID-19 pandemic.”
- terminated · 2020-05-13 · Alexion Pharmaceuticals, Inc. · matched by the registry's drug synonyms“Focus resources on a planned phase 2/3 study”
- terminated · 2020-02-05 · Alexion Pharmaceuticals, Inc. · matched by the registry's drug synonyms“Study objectives achieved”
Paediatric incentives and obligations for FCGRT's drugs
For nipocalimab, efgartigimod alfa, rozanolixizumab, batoclimab, orilanolimab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · FCGRT is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMA/PE/0000238984 (nipocalimab, Treatment of myasthenia gravis): PM: decision on the application for modification of an agreed PIP, 14 Apr 2025; EMA/PE/0000231366 (efgartigimod alfa, Treatment of myasthenia gravis): PM: decision on the application for modification of an agreed PIP, 21 Mar 2025; EMA/PE/0000225023 (efgartigimod alfa, Treatment of Sjögren's syndrome): W: decision granting a waiver in all age groups for all conditions or indications, 3 Jan 2025; EMA/PE/0000227425 (efgartigimod alfa, Treatment of immune thrombocytopenia): PM: decision on the application for modification of an agreed PIP, 28 Jan 2025; +17 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/26/3259 positive 28 Jul 2026: Treatment of myelin oligodendrocyte glycoprotein antibody-associated disease; EU/3/25/3045 positive date not given: Prevention of fetal and neonatal alloimmune thrombocytopenia; EU/3/22/2684 positive 10 Aug 2022: Treatment of myasthenia gravis; EU/3/18/2131 withdrawn 11 Jan 2019: Treatment of immune thrombocytopenia; +5 moreRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Vyvgart: authorised since 10 Aug 2022, orphan medicine; Imaavy: authorised since 28 Nov 2025; Rystiggo: authorised since 5 Jan 2024, orphan medicineRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of nipocalimab, efgartigimod alfa, rozanolixizumab, batoclimab, orilanolimabRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 5 interventional studies of nipocalimab, efgartigimod alfa, rozanolixizumab, batoclimab, orilanolimab include patients under 18; 4 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 5 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.